JP2017523202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523202A5 JP2017523202A5 JP2017505491A JP2017505491A JP2017523202A5 JP 2017523202 A5 JP2017523202 A5 JP 2017523202A5 JP 2017505491 A JP2017505491 A JP 2017505491A JP 2017505491 A JP2017505491 A JP 2017505491A JP 2017523202 A5 JP2017523202 A5 JP 2017523202A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disorders
- group
- disorder
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 150000001875 compounds Chemical class 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 208000011117 substance-related disease Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 208000027626 Neurocognitive disease Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 206010020765 hypersomnia Diseases 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 claims 3
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- -1 2-pyridinyl Chemical group 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000027674 Schizophrenia Spectrum and Other Psychotic disease Diseases 0.000 claims 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179602.9 | 2014-08-01 | ||
| EP14179602 | 2014-08-01 | ||
| PCT/EP2015/067538 WO2016016383A1 (en) | 2014-08-01 | 2015-07-30 | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523202A JP2017523202A (ja) | 2017-08-17 |
| JP2017523202A5 true JP2017523202A5 (enExample) | 2018-09-06 |
| JP6661605B2 JP6661605B2 (ja) | 2020-03-11 |
Family
ID=51257441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505491A Expired - Fee Related JP6661605B2 (ja) | 2014-08-01 | 2015-07-30 | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10017514B2 (enExample) |
| EP (1) | EP3174884B1 (enExample) |
| JP (1) | JP6661605B2 (enExample) |
| CN (1) | CN107001373B (enExample) |
| AU (1) | AU2015295301B2 (enExample) |
| CA (1) | CA2954222C (enExample) |
| ES (1) | ES2702194T3 (enExample) |
| RU (1) | RU2696135C2 (enExample) |
| WO (1) | WO2016016383A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JP6861154B2 (ja) | 2014-12-03 | 2021-04-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射標識されたｍＧｌｕＲ２ ＰＥＴリガンド |
| JP6689856B2 (ja) | 2014-12-03 | 2020-04-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 |
| JP6929285B2 (ja) | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド |
| LT3389727T (lt) | 2015-12-18 | 2020-10-12 | Janssen Pharmaceutica Nv | Radioaktyviai pažymėti mglur2/3 pet ligandai |
| US9849817B2 (en) | 2016-03-16 | 2017-12-26 | Ford Global Technologies, Llc | Composite seat structure |
| WO2019054411A1 (ja) | 2017-09-13 | 2019-03-21 | 日本電気株式会社 | リチウムイオン二次電池 |
| EP3719023B1 (en) | 2017-11-24 | 2024-10-16 | Sumitomo Pharma Co., Ltd. | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004054665A1 (de) * | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| WO2012083224A1 (en) * | 2010-12-17 | 2012-06-21 | Vanderbilt University | Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors |
| MX344308B (es) | 2011-11-03 | 2016-12-13 | Merck Sharp & Dohme | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| WO2013192347A1 (en) * | 2012-06-20 | 2013-12-27 | Vanderbilt University | Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| WO2013192350A1 (en) * | 2012-06-20 | 2013-12-27 | Vanderbilt University | Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors |
| WO2013192343A1 (en) * | 2012-06-20 | 2013-12-27 | Vanderbilt University | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors |
| KR20150070187A (ko) | 2012-10-23 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제 |
| WO2016016382A1 (en) * | 2014-08-01 | 2016-02-04 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors |
-
2015
- 2015-07-30 EP EP15747422.2A patent/EP3174884B1/en active Active
- 2015-07-30 WO PCT/EP2015/067538 patent/WO2016016383A1/en not_active Ceased
- 2015-07-30 CA CA2954222A patent/CA2954222C/en active Active
- 2015-07-30 JP JP2017505491A patent/JP6661605B2/ja not_active Expired - Fee Related
- 2015-07-30 RU RU2017106100A patent/RU2696135C2/ru active
- 2015-07-30 US US15/500,205 patent/US10017514B2/en active Active
- 2015-07-30 CN CN201580041312.XA patent/CN107001373B/zh not_active Expired - Fee Related
- 2015-07-30 AU AU2015295301A patent/AU2015295301B2/en not_active Ceased
- 2015-07-30 ES ES15747422T patent/ES2702194T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526659A5 (enExample) | ||
| EP2651899B1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| CN108699057B (zh) | 5-取代的2-(吗啉-4-基)-1,7-萘啶 | |
| JP2017523201A5 (enExample) | ||
| AU2017261336B2 (en) | Modulators of the integrated stress pathway | |
| CN108137590B (zh) | 作为mdm2-p53抑制剂的新的螺(3h-吲哚-3,2′-吡咯烷)-2(1h)-酮化合物及其衍生物 | |
| ES2648876T3 (es) | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo | |
| JP2017522340A5 (enExample) | ||
| RU2017106489A (ru) | 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2 | |
| JP2017528515A5 (enExample) | ||
| RU2017106100A (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИН-4(5Н)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
| EP3133075B1 (en) | Fused heterocyclic compound | |
| EP3489237B1 (en) | 4-azaindole derivatives | |
| KR102148679B1 (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법 | |
| HRP20171051T1 (hr) | Spojevi 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona i njihova uporaba kao negativnih alosternih modulatora receptora mglur2 | |
| CA2810755A1 (en) | Substituted imidazopyridazines | |
| JP2014051516A (ja) | タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体 | |
| RS56720B1 (sr) | Jedinjenja i kompozicije za lečenje parazitskih oboljenja | |
| WO2016077375A1 (en) | Bromodomain inhibitors and uses thereof | |
| JP2014501769A (ja) | 縮合アミノジヒドロチアジン誘導体 | |
| WO2014147586A1 (en) | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh | |
| JP2017536399A5 (enExample) | ||
| JP2020514377A (ja) | ピリミジニル−ピリジルオキシ−ナフチル化合物及びｉｒｅ１関連疾患及び障害を治療する方法 | |
| RU2017123038A (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
| RU2015101512A (ru) | Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5 |